Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD

Ophthalmology

Volumn 123, Issue 1, 2016, Pages 60-69

  Waldstein, Sebastian M ^a   Wright, Jonathan ^b   Warburton, James ^c   Margaron, Philippe ^c   Simader, Christian ^a   Schmidt Erfurth, Ursula ^a  

^a INSTITUTE FOR MICROELECTRONICS   (Austria)

^b Numerus Statistics Ltd   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; RETINAL; ANGIOGENESIS INHIBITOR;

ADHESION; ADULT; AGE RELATED MACULAR DEGENERATION; CENTRAL RETINAL THICKNESS; CONFERENCE PAPER; DIABETIC RETINOPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPHTHALMOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETINA DETACHMENT; VISUAL ACUITY; VITREOUS BODY DETACHMENT; ADOLESCENT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINAL NEOVASCULARIZATION; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RANIBIZUMAB; RETINA; RETINAL NEOVASCULARIZATION; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84951033157     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.09.013     Document Type: Conference Paper

References (31)

1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106-16.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
4. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5.
5. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
6. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-324.e1.
7. Hariprasad SM, Morse LS, Shapiro H, et al. Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age-related macular degeneration. J Ophthalmol 2012;2012:690641.
8. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119: 1388-98.
9. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56.
10. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122:146-52.
11. Abedi F, Wickremasinghe S, Islam AF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 2014;34:1531-8.
12. Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 2014;121:1237-45.
13. Sakata LM, Deleon-Ortega J, Sakata V, Girkin CA. Optical coherence tomography of the retina and optic nerve: a review. Clin Exp Ophthalmol 2009;37:90-9.
14. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on antivascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology 2011;118: 101-10.
15. Mayr-Sponer U, Waldstein SM, Kundi M, et al. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology 2013;120:2620-9.
16. Waldstein SM, Ritter M, Simader C, et al. Impact of vitreomacular adhesion on ranibizumab mono-and combination therapy for neovascular age-related macular degeneration. Am J Ophthalmol 2014;158:328-336.e1.
17. Cuilla TA, Ying GS, Maguire MG, et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2015;122:1203-11.
18. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9.
19. Ritter M, Elledge J, Simader C, et al. Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres. Br J Ophthalmol 2011;95:381-5.
20. Itakura H, Kishi S. Evolution of vitreomacular detachment in healthy subjects. JAMA Ophthalmol 2013;131:1348-52.
21. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
22. Kiss CG, Geitzenauer W, Simader C, et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50:2376-83.
23. Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120: 1860-70.
24. Schmidt-Erfurth U, Waldstein SM, Deak GG, et al. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 2015;122:822-32.
25. Takahashi H, Nomura Y, Tan X, et al. Effects of posterior vitreous detachment on aqueous humour levels of VEGF and inflammatory cytokines. Br J Ophthalmol 2015;99:1065-9.
26. Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121:150-61.
27. Jang L, Gianniou C,Ambresin A,Mantel I. Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. Graefes Arch Clin Exp Ophthalmol 2015;253:1211-6.
28. Kim BJ, Ying GS, Huang J, et al. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol 2014;158: 128-135.e10.
29. Ying GS, Kim BJ, Maguire MG, et al. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 2014;132:915-21.
30. Mojana F, Cheng L, Bartsch D-UG, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol 2008;146:218-227.e1.
31. Roberts P, Mittermueller TJ, Montuoro A, et al. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD. Invest Ophthalmol Vis Sci 2014;55:6623-30.